Concord Drugs reports mixed financial results
Concord Drugs, a microcap pharmaceutical company, has reported a decrease in net sales by 16.04% for the quarter ended September 2023. However, its standalone net profit and operating profit have shown positive growth. The company's stock call is 'Hold' according to MarketsMojo, with some positive indicators but also areas for improvement.
Concord Drugs, a microcap pharmaceutical company, has recently declared its financial results for the quarter ended September 2023. The company's net sales for the quarter have decreased by 16.04% compared to the previous quarter, but its standalone net profit has shown a growth of 8.16%. The operating profit (PBDIT) has also seen a positive growth of 8.57% compared to the previous quarter.
According to MarketsMOJO, a leading financial analysis platform, the stock call for Concord Drugs is 'Hold'. The company's financial performance for the quarter has been flat, but there are some positive indicators that are working in its favor. The company has generated the highest operating cash flow in the last three years and its operating profit margin has also improved. The profit before tax (PBT) and profit after tax (PAT) have also shown positive trends in the near term.
However, there are also some areas that need improvement for Concord Drugs. The net sales for the quarter have fallen by 45.12% compared to the same quarter last year and have been consistently decreasing in the last five quarters. This indicates a negative trend in the company's sales performance.
Overall, Concord Drugs has shown a mixed financial performance for the quarter ended September 2023. While there are some positive indicators, there are also areas that need improvement. Investors are advised to hold their position in the company's stock and keep an eye on its future financial results.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
